Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?
- PMID:26598309
- DOI: 10.1016/j.ogc.2015.07.007
Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?
Abstract
Combined hormonal contraceptives (CHCs) use a combination of estrogen and progestogen to provide contraception. The most important risk of using CHCs is venous thromboembolism (VTE). It is unclear whether the type of progestogen used in a method augments that risk. Although the evidence supporting an increase in thrombosis risk is not conclusive, neither is the evidence supporting the benefit of newer progestogens in terms of tolerability or continuation. The benefits of CHCs outweigh the risks and the absolute risk of VTE remains small. A balanced discussion of potential risks and benefits of particular CHC formulations is warranted during contraception counseling.
Keywords: Drospirenone; Oral contraceptive; Progestin; Progestogen; Venous thromboembolism.
Copyright © 2015 Elsevier Inc. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical